The inhibition of CD38 enzymatic activity, blocking the CD38-mediated Ca2+ signaling, has been proposed as a pharmacologic strategy in different conditions, including, but not limited to, allergic airway disease [13], cardiovascular diseases [14], vascular thrombosis, disordered inflammation, and aberrant immune reactivity [15]. This evidence concerns the gene CD38 and cardiovascular disorder.